Back to Search Start Over

Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer.

Authors :
Fransen, Marieke F.
Cordfunke, Robert A.
Sluijter, Marjolein
van Steenbergen, Mies J.
Drijfhout, Jan W.
Ossendorp, Ferry
Hennink, Wim E.
Melief, Cornelis J.M.
Source :
Vaccine. Mar2014, Vol. 32 Issue 15, p1654-1660. 7p.
Publication Year :
2014

Abstract

Highlights: [•] We compare two slow-release agents, Montanide ISA 51 and dextran-based microparticles. [•] CD40 agonistic antibody is delivered locally as treatment for tumors. [•] Both agents reduce side-effects of high serum levels of CD40 antibody. [•] Dextran microparticles cause inflammation associated with enhanced tumor-outgrowth. [•] Montanide ISA 51 is the preferred slow-release agent for this treatment. [ABSTRACT FROM AUTHOR]

Subjects

Subjects :
*CANCER immunotherapy
*CD40 antigen
*IMMUNOGLOBULINS
*CONTROLLED release drugs
*DRUG efficacy
*DRUG side effects
*BLOOD serum analysis

Details

Language :
English
ISSN :
0264410X
Volume :
32
Issue :
15
Database :
Academic Search Index
Journal :
Vaccine
Publication Type :
Academic Journal
Accession number :
94897396
Full Text :
https://doi.org/10.1016/j.vaccine.2014.01.056
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details